Skip to main content
Clinical Trials/ACTRN12619000890134
ACTRN12619000890134
Recruiting
未知

A Prospective, Single-arm, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPointTM Reperfusion SystemTM for Aspiration Embolectomy in Acute Ischemic Stroke Patients

Route 92 Medical, Inc.0 sites15 target enrollmentJune 26, 2019

Overview

Phase
未知
Intervention
Not specified
Conditions
Acute Ischemic Stroke
Sponsor
Route 92 Medical, Inc.
Enrollment
15
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 26, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.The consent process has been completed with the subject, Legally Authorized Representative, or two physician best interest and consent is documented
  • 2\.Age \>\=18 years
  • 3\.Clinical signs consistent with an acute ischemic stroke
  • 4\.Baseline National Institutes of Health Stroke Scale (NIHSS) score ? 6
  • 5\.Pre\-stroke modified Rankin Score (mRS) ? 2
  • 6\.Acute occlusion of the middle cerebral artery (MCA), internal carotid artery (ICA), vertebral or basilar arteries confirmed via computed tomography angiography (CTA) and/or magnetic resonance angiography (MRA)
  • 7\.The Investigator estimates that at least one delivery of the Route 92 Medical Reperfusion System can be completed within 24 hours of time last known well
  • 8\.In the opinion of the Investigator, reperfusion of the ischemic territory will result in clinical benefit
  • 9\.Angiographic confirmation of an occlusion or near occlusion of the middle cerebral artery, internal carotid artery, vertebral or basilar arteries with a modified Thrombolysis In Cerebral Infarction (mTICI) scale score of 0\-1

Exclusion Criteria

  • 1\.Known pregnancy or breast feeding
  • 2\.Known comorbidity that may complicate treatment or prevent improvement or follow\-up
  • 3\.Known life expectancy \< 12 months
  • 4\.Known history of severe allergy to contrast medium
  • 5\.Subject known to have suffered a stroke in the past 90 days
  • 6\.Subject participating in another study involving an investigational device or drug.
  • 7\.Known connective tissue disorder affecting the arteries (e.g. Marfan syndrome, fibromuscular dysplasia, Ehlers\-Danlos syndrome)
  • 8\.Any known pre\-existing hemorrhagic or coagulation deficiency
  • 9\.Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage
  • 10\.Baseline CT or MRI showing intracranial tumor (except small meningioma)

Outcomes

Primary Outcomes

Not specified

Similar Trials